21st century cures bill to cost $869M for rare disease drug marketing

Meeting unmet medical needs has its price. Consider the 21st Century Cures legislation. The sweeping Congressional bill, which is designed to jumpstart medical innovation, has a provision that would allow the FDA to grant an extra six months of exclusive marketing rights to a company if an existing drug is approved to treat a rare disease. Jerry Avorn, professor of medicine at Brigham and Women’s Hospital, is quoted.

Read the full article